logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Diffuse Large Bcell Lymphoma

    FiltersReset Filters
    6 results

    • columvi

      (Glofitamab)
      Genentech, Inc.
      Usage: COLUMVI is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL, NOS) or large B-cell lymphoma from follicular lymphoma, following two or more lines of systemic therapy. This indication is granted under accelerated approval, pending further confirmation of clinical benefit.

    • epkinly

      (epcoritamab-bysp)
      Genmab US, Inc.
      Usage: EPKINLY is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after two or more systemic therapies, as well as for relapsed or refractory follicular lymphoma (FL) after similar treatment. Approval is based on response rates and durability.

    • polivy

      (polatuzumab vedotin)
      Genentech, Inc.
      Usage: POLIVY is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL), and for those with relapsed or refractory DLBCL, NOS, after at least two prior therapies, in combination with specific regimens.

    • rituxan hycela

      (rituximab and hyaluronidase)
      Genentech, Inc.
      Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.

    • ruxience

      (rituximab-pvvr)
      Pfizer Laboratories Div Pfizer Inc
      Usage: RUXIENCE is indicated for adult patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis, often in combination with other therapies, depending on the specific condition and patient response.

    • xpovio

      (selinexor)
      Karyopharm Therapeutics Inc.
      Usage: XPOVIO is indicated for adults with multiple myeloma who have had prior therapy, in combination with bortezomib and dexamethasone, or dexamethasone alone for heavily pretreated patients. It is also approved for relapsed or refractory diffuse large B-cell lymphoma after at least two systemic therapies.